CJC-1295 research follows a longer signal
In healthy-adult studies, a long-acting CJC-1295 preparation raised hormones for days. That still leaves the question of whether anyone benefits.
Which CJC-1295 are we talking about?
The name needs a little unpacking. CJC-1295 is based on a hormone that tells the pituitary gland to release growth hormone. The pituitary is a small gland at the base of the brain.
One form has an attachment called DAC. It latches onto albumin, a common blood protein, so the compound stays around longer. The FDA review distinguishes forms with and without that attachment. They aren’t interchangeable.
FDA couldn’t pin down the exact form used in the human studies. It appeared to be the long-acting DAC form. The results don’t tell us what a preparation without DAC would do. Before asking whether CJC-1295 works, I want to know which form the question is about.
What did the hormone studies show?
In a study of healthy adults, CJC-1295 raised growth hormone for days. It also raised IGF-1, a related growth signal.
A second study in healthy men looked at the pattern. Growth hormone still arrived in bursts, even with the longer-lasting stimulation. The background level could rise while the usual pulses remained.
That’s an interesting finding about how the body responds. It doesn’t establish better sleep, more muscle or longer life. Keeping a recognisable rhythm also doesn’t mean the treatment is harmless. The studies measured hormones; the everyday benefits people ask about still need evidence that measures those benefits.
What belongs beside those findings?
The FDA assessment describes reported headaches, flushing, dizziness, low blood pressure and increased heart rate. These aren’t details I’d leave at the bottom of a cheerful hormone story. Long-term safety in people remains unknown.
There’s also a naming trap in the regulatory record. On FDA’s page dated April 22, 2026, CJC-1295 appears among substances whose nominations were withdrawn. The safety concerns are still there beside it.
Withdrawal isn’t clearance, a move to Category 1 or permission to compound it. FDA gives no individual withdrawal date. CJC-1295 has no FDA approval. A different label on a list doesn’t resolve the health question.
A useful place to pause
A result about staying power is a beginning. The next study needs a practical question.
I’d finish with the outcome, rather than the duration: what would make this hormone change worthwhile? The research here leaves that open. The comparison page helps keep the exact preparation, the measured change and the hoped-for benefit together.